Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.78 |
| ▸ | EED | O75530 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CCR3 | P51677 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL892689 | 1.00 | GBA1 (0.78) | GBA1EEDKDM1AMAOBSLC6A2 | |
| SCHEMBL4889591 | 1.00 | GBA1 (0.78) | GBA1EEDKDM1AMAOBSLC6A2 | |
| SCHEMBL31524060 | 0.89 | GBA1 (0.62) | GBA1EEDKDM1AMAOBHRH4 | |
| SCHEMBL1761058 | 0.89 | EED (0.61) | GBA1EEDSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3473180 | 0.89 | EED (0.61) | GBA1EEDSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8547993 | 0.89 | EED (0.61) | GBA1EEDSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9828599 | 0.88 | GBA1 (0.64) | GBA1EEDSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL87612 | 0.88 | GBA1 (1.00) | GBA1SLC6A4POLBCCR3 | |
| SCHEMBL9598369 | 0.87 | GBA1 (0.59) | GBA1EEDSLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL3914926 | 0.87 | EED (0.60) | GBA1EEDSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9611214-B2 | N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-04-04 | — | — | US | disclosed |
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | PFIZER INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | EFREMOV IVAN | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | PAICS, TMBIM6, ABCG2 | GBA1 69/4885EED 3404/4885KDM1A 3628/4885 |
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | AZI2, PAICS, UGT2B7 | GBA1 184/4885EED 1102/4885KDM1A 2147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.